Simvastatin inhibited bladder cancer cell metastasis by blocking epithelial-mesenchymal transition (EMT) and disrupting AKT/GSK3β pathways, while also suppressing cell proliferation and causing G1/G0 phase cell cycle arrest through the Peroxisome Proliferator-Activated Receptor (PPAR)γ signaling pathway (Wang et al., 2016). Here, AKT1 is linked to urinary bladder carcinoma.